Table 1. Gene expression values from vehicle and PDGFR inhibitor treated muscles.
| Gene | 3 day control | 3 day treatment | 10 day control | 10 day treatment |
|---|---|---|---|---|
| Angiogenesis | ||||
| Cd248 | 4.3±2.0 | 1.6±0.6a | 3.1±1.3b | 1.5±0.2a,c |
| Pecam1 | 1.5±0.4 | 1.3±0.4 | 1.6±0.5 | 1.2±0.2 |
| Tsp1 | 9.6±4.3 | 9.4±3.3 | 2.5±0.7a,b | 3.4±1.0a,b |
| Vegfa | 0.6±0.2 | 0.6±0.3 | 0.7±0.6 | 0.4±0.2 |
| Atrophy and Myogenesis | ||||
| Fboxo30 | 1.2±0.4 | 1.1±0.3 | 1.2±0.4 | 0.8±0.1 |
| Fboxo32 | 0.3±0.1 | 0.4±0.2a | 0.5±0.1a | 0.3±0.1b,c |
| Gdf11 | 1.1±0.1 | 0.7±0.1 | 2.3±0.7a,b | 1.0±0.2c |
| Tmem8c | 38.3±10.6 | 15.1±15.0a | 14.4±7.1a | 5.3±2.4a |
| Trim63 | 1.2±0.3 | 1.0±0.2 | 0.9±0.3 | 0.6±0.1a,b |
| Extracellular Matrix | ||||
| Col1a1 | 8.6±4.6 | 0.2±0.4a | 14.6±10.1b | 0.4±0.8a,c |
| Col3a1 | 7.6±3.6 | 3.4±1.5 | 8.7±5.4b | 2.5±0.6a,c |
| Col4a1 | 3.1±1.2 | 1.9±0.7 | 3.6±1.4b | 1.1±0.2a,c |
| Col5a1 | 7.8±4.3 | 3.1±1.5a | 8.2±5.0b | 1.7±0.4a,c |
| Col6a1 | 3.7±1.6 | 1.6±0.8 | 5.1±2.8b | 1.2±0.2a,c |
| Eln | 3.6±0.7 | 2.9±1.4 | 4.6±1.8 | 2.2±0.4c |
| Has1 | 47.5±40.4 | 52.4±33.7 | 8.1±7.1a,b | 3.7±1.3a,b |
| Has2 | 4.9±4.0 | 4.1±1.9 | 2.7±1.6 | 1.1±0.2a |
| Hyal1 | 0.9±0.3 | 0.7±0.2 | 1.8±0.5a,b | 0.8±0.1c |
| Lox | 26.8±13.9 | 12.6±6.3a | 6.0±4.3a | 3.0±0.4a |
| Mmp2 | 1.2±0.4 | 0.9±0.2 | 4.1±2.3a,b | 1.4±0.3c |
| Mmp3 | 13.6±7.1 | 9.8±6.9 | 19.5±11.8 | 17.9±4.3 |
| Mmp8 | 5.6±5.3 | 23.9±10.2a | 1.2±0.5b | 22.2±5.0a,c |
| Mmp9 | 4.6±5.4 | 4.4±1.4 | 1.0±0.4 | 6.0±0.9c |
| Mmp13 | 5.1±3.6 | 2.2±1.0 | 4.1±2.4 | 2.5±1.6 |
| Mmp14 | 6.0±3.6 | 2.8±1.2 | 11.7±10.2b | 2.6±0.8c |
| Timp1 | 143.0±75.1 | 65.6±41.6a | 14.1±8.7a | 7.7±1.2a |
| Timp2 | 2.0±0.9 | 1.2±0.4 | 2.8±1.3b | 1.2±0.3c |
| Fibroblast Markers | ||||
| Fap | 1.2±0.4 | 0.9±0.2 | 1.7±0.6b | 0.8±0.1c |
| Fsp1 | 11.7±6.4 | 4.4±2.4a | 5.0±2.4a | 2.5±0.9a |
| Immune Cell Markers | ||||
| Cd11b | 15.9±7.3 | 8.3±4.8a | 3.0±1.1a | 1.9±0.4a,b |
| Cd68 | 23.3±7.3 | 24.8±5.1 | 3.1±1.6a,b | 1.7±0.4a,b |
| Cd163 | 4.9±2.3 | 3.3±1.4 | 2.5±1.2a | 1.5±0.2a |
| Cd206 | 12.1±5.5 | 6.8±3.9a | 4.2±2.0a | 2.0±0.5a |
| F480 | 0.9±0.1 | 0.8±0.1 | 1.3±0.3a,b | 1.0±0.1 |
| Ly6c | 1.3±0.4 | 1.1±0.2 | 1.6±0.6 | 1.0±0.1 |
Target gene expression was normalized to the stable housekeeping gene Hspb6, and further normalized to muscles that were not subjected to synergist ablation. Values are mean±SD, N = 6–8 muscles for each group. Differences between groups were tested using a two-way ANOVA (α = 0.05) followed by Holm-Sidak post hoc sorting:
a
different from 3 day control;
b
different from 3 day PDGFR inhibitor treatment;
c
different from 10 day control.